Rafferty Asset Management’s Aldeyra Therapeutics ALDX Stock Holding History

Rafferty Asset Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-268,690	Closed	-$1.79M	–	1073
2023 Q3	$1.79M	Buy	268,690 +15,469	+6%	+$115K	0.01%	640
2023 Q2	$2.12M	Buy	+253,221	New	+$2.49M	0.01%	624
2022 Q1	–	Sell	-212,975	Closed	-$852K	–	1219
2021 Q4	$852K	Buy	212,975 +68,152	+47%	+$520K	﹤0.01%	937
2021 Q3	$1.27M	Buy	144,823 +11,400	+9%	+$105K	0.01%	753
2021 Q2	$1.51M	Sell	133,423 -29,427	-18%	-$354K	0.01%	760
2021 Q1	$1.94M	Buy	+162,850	New	+$1.88M	0.01%	638

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rafferty Asset Management's ALDX Position: Q4 2023 in Review

Rafferty Asset Management sold out of Aldeyra Therapeutics (ALDX) in Q4 2023, closing a stake of 268,690 shares — an estimated $1.79M sold.

Rafferty Asset Management first reported a position in ALDX in Q1 2021 and held it in 6 quarters. The position peaked at $2.12M in Q2 2023. 105 funds tracked by Wall St. Rank hold ALDX as of Q4 2023.

Rafferty Asset Management reported no remaining Aldeyra Therapeutics position as of Q4 2023 after selling out during the quarter.
Rafferty Asset Management sold 268,690 Aldeyra Therapeutics shares in Q4 2023, an estimated $1.79M.
Rafferty Asset Management first reported a position in Aldeyra Therapeutics in Q1 2021 and held it in 6 quarters.
Rafferty Asset Management's Aldeyra Therapeutics position peaked at $2.12M in Q2 2023.
105 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2023.

Based on Rafferty Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.